Xiamen Kingdomway Group Past Earnings Performance
Past criteria checks 4/6
Xiamen Kingdomway Group's earnings have been declining at an average annual rate of -16%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 0.6% per year. Xiamen Kingdomway Group's return on equity is 6.6%, and it has net margins of 8.5%.
Key information
-16.0%
Earnings growth rate
-15.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -0.6% |
| Return on equity | 6.6% |
| Net Margin | 8.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Xiamen Kingdomway Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3,055 | 261 | 754 | 60 |
| 31 Dec 23 | 3,103 | 277 | 739 | 58 |
| 30 Sep 23 | 3,025 | 152 | 673 | 64 |
| 30 Jun 23 | 2,997 | 167 | 672 | 60 |
| 31 Mar 23 | 3,058 | 223 | 658 | 65 |
| 31 Dec 22 | 3,009 | 257 | 651 | 72 |
| 30 Sep 22 | 3,216 | 472 | 663 | 86 |
| 30 Jun 22 | 3,404 | 556 | 628 | 89 |
| 31 Mar 22 | 3,456 | 609 | 605 | 90 |
| 31 Dec 21 | 3,616 | 789 | 599 | 83 |
| 30 Sep 21 | 3,640 | 830 | 572 | 80 |
| 30 Jun 21 | 3,673 | 971 | 569 | 75 |
| 31 Mar 21 | 3,605 | 1,042 | 559 | 73 |
| 31 Dec 20 | 3,504 | 959 | 548 | 74 |
| 30 Sep 20 | 3,464 | 717 | 579 | 76 |
| 30 Jun 20 | 3,246 | 575 | 572 | 73 |
| 31 Mar 20 | 3,320 | 537 | 569 | 68 |
| 31 Dec 19 | 3,192 | 451 | 553 | 66 |
| 30 Sep 19 | 3,090 | 564 | 503 | 64 |
| 30 Jun 19 | 3,096 | 567 | 521 | 66 |
| 31 Mar 19 | 2,789 | 480 | 486 | 66 |
| 31 Dec 18 | 2,873 | 687 | 437 | 69 |
| 30 Sep 18 | 2,792 | 885 | 421 | 59 |
| 30 Jun 18 | 2,510 | 815 | 323 | 76 |
| 31 Mar 18 | 2,419 | 746 | 317 | 62 |
| 31 Dec 17 | 2,085 | 474 | 327 | 47 |
| 30 Sep 17 | 1,836 | 345 | 315 | 31 |
| 30 Jun 17 | 1,762 | 319 | 328 | 0 |
| 31 Mar 17 | 1,704 | 318 | 316 | 0 |
| 31 Dec 16 | 1,663 | 300 | 303 | 0 |
| 30 Sep 16 | 1,570 | 196 | 337 | 0 |
| 30 Jun 16 | 1,464 | 157 | 326 | 0 |
| 31 Mar 16 | 1,330 | 119 | 308 | 0 |
| 31 Dec 15 | 1,204 | 113 | 290 | 0 |
| 30 Sep 15 | 1,078 | 159 | 206 | 0 |
| 30 Jun 15 | 981 | 178 | 183 | 0 |
| 31 Mar 15 | 899 | 192 | 159 | 0 |
| 31 Dec 14 | 838 | 195 | 140 | 0 |
| 30 Sep 14 | 783 | 184 | 125 | 0 |
| 30 Jun 14 | 759 | 168 | 123 | 0 |
| 31 Mar 14 | 703 | 129 | 116 | 0 |
| 31 Dec 13 | 670 | 102 | 112 | 0 |
| 30 Sep 13 | 657 | 82 | 96 | 0 |
| 30 Jun 13 | 657 | 74 | 94 | 0 |
Quality Earnings: 002626 has high quality earnings.
Growing Profit Margin: 002626's current net profit margins (8.5%) are higher than last year (7.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002626's earnings have declined by 16% per year over the past 5 years.
Accelerating Growth: 002626's earnings growth over the past year (16.6%) exceeds its 5-year average (-16% per year).
Earnings vs Industry: 002626 earnings growth over the past year (16.6%) exceeded the Pharmaceuticals industry -0.01%.
Return on Equity
High ROE: 002626's Return on Equity (6.6%) is considered low.